June 24, 2026 Cleveland Clinic, Pulmonary Hypertension: Symptoms & Treatment , accessed June 29, 2026 Mayo Clinic, Pulmonary hypertension - Diagnosis and treatment , accessed June 30, 2026 ClinicalTrials.gov , Study Details | NCT06354660 | Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) , accessed June 26, 2026 The University of Alabama at Birmingham, The GLP-1 revolution: What UAB researchers are discovering about how these drugs work , June 30, 2026 Journal of Diabetes Investigation via PubMed, GIP and GLP1, the two incretin hormones: Similarities and differences , April 2010 Cleveland Clinic, GLP-1 Agonists , accessed June 29, 2026 Eli Lilly, Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial , May 21, 2026 The New York Times, Experimental Drug Yields Dramatic Weight Loss , May 21, 2026 National Institutes of Health, agonist , accessed June 26, 2026 GoodRx, Zepbound vs
Compounded Tirzepatide Tirzepatide is a dual GIP/GLP-1 receptor agonist the same active ingredient in brand-name Mounjaro and Zepbound
Pre made protein shakes (ready to drink) require zero effort and deliver 25 to 30 grams per bottle
Key Outcomes: Up to 24.2% total body weight reduction in high-dose groups
